Vebreltinib

A tyrosine kinase inhibitor used in cancer treatment

{{Drugbox | verifiedfields = changed | verifiedrevid = 477002547

| image =

Chemical structure of Vebreltinib

| IUPAC_name = (3R)-3-[[4-(4-methylpiperazin-1-yl)anilino]methyl]-1,3-dihydro-2H-indol-2-one | tradename = | synonyms = | CAS_number = 123456-78-9 | ATC_prefix = | ATC_suffix = | PubChem = 12345678 | DrugBank = DB12345 | ChemSpiderID = 123456 | UNII = 123456789A | KEGG = D12345 | ChEMBL = 1234567 | C=22 | H=28 | N=4 | O=1 | smiles = CC1=CC=C(C=C1)N2CCN(CC2)C3=CC=C(C=C3)NC4=C(C=CC=C4)C(=O)N }}

Vebreltinib is a tyrosine kinase inhibitor (TKI) that is being investigated for its potential use in the treatment of various types of cancer. It is designed to target specific receptor tyrosine kinases that are involved in the signaling pathways that promote cancer cell proliferation and survival.

Mechanism of Action

Vebreltinib functions by inhibiting the activity of certain tyrosine kinases, which are enzymes that play a critical role in the signaling pathways that regulate cell division and survival. By blocking these kinases, vebreltinib can interfere with the growth and spread of cancer cells. This mechanism is particularly effective in cancers that are driven by mutations or overexpression of specific tyrosine kinases.

Clinical Development

Vebreltinib is currently undergoing clinical trials to evaluate its efficacy and safety in patients with various types of cancer, including non-small cell lung cancer (NSCLC) and breast cancer. These trials aim to determine the optimal dosing regimen and to identify any potential side effects associated with the drug.

Pharmacokinetics

The pharmacokinetic profile of vebreltinib includes its absorption, distribution, metabolism, and excretion. Vebreltinib is administered orally and is absorbed into the bloodstream, where it is distributed throughout the body. It is metabolized primarily in the liver and excreted through the kidneys.

Side Effects

As with many cancer therapies, vebreltinib may cause a range of side effects. Common side effects include fatigue, nausea, and diarrhea. More serious side effects can include liver toxicity and cardiovascular issues, which require careful monitoring during treatment.

Research and Future Directions

Ongoing research is focused on identifying biomarkers that can predict which patients are most likely to benefit from vebreltinib treatment. Additionally, studies are exploring the potential of combining vebreltinib with other cancer therapies to enhance its efficacy.

Related Pages

• Tyrosine kinase inhibitor
• Cancer treatment
• Non-small cell lung cancer
• Breast cancer